Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "neurological-disorders"

22 News Found

Novartis, Voyager Therapeutics reach license deal for gene therapy vectors to combat neurological diseases
Biotech | March 09, 2022

Novartis, Voyager Therapeutics reach license deal for gene therapy vectors to combat neurological diseases

Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders

Biogen exercises option with Ionis for spinal muscular atrophy
Biotech | January 05, 2022

Biogen exercises option with Ionis for spinal muscular atrophy

Biogen paid Ionis a US $ 60 million one-time upfront payment

Latest Stories

BMS’ Cobenfy sees steady start, eyes stronger growth ahead

Merck’s Capvaxive shows strong momentum amid industry vaccine decline

FDA rejects Regeneron’s Eylea HD pre-filled syringe application amid manufacturing setbacks

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Advances in genetic testing, fertility preservation, and ART are reshaping reproductive care across India: Dr. Umesh N Jindal, Director, Jindal IVF
Advances in genetic testing, fertility preservation, and ART are reshaping reproductive care across India: Dr. Umesh N Jindal, Director, Jindal IVF
Dr. Umesh N Jindal Director, Jindal IVF
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India

Packaging